YHP 2205
Alternative Names: YHP-2205Latest Information Update: 10 May 2024
At a glance
- Originator Yuhan ANZ
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 17 Apr 2024 Preclinical trials in Unspecified in Australia (PO) (NCT06359626)
- 11 Apr 2024 Yuhan Corporation plans phase-I bioequivalence trial (In volunteers) in July 2024 (PO) (NCT06359626)